IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (the “Company”) (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the fourth quarter and fiscal year ended December 31, 2018. Global revenue in the fourth quarter of 2018 was $34.7 million, a 21.2% decrease from $44.0 million in the […]
Other News
Corindus Vascular Robotics Announces Closing of Private Placement for $15 Million
WALTHAM, Mass.–(BUSINESS WIRE)–Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American:CVRS), a leading developer of precision vascular robotics, today announced the execution of a private placement transaction with a large institutional investor pursuant to which it will sell and issue an aggregate of 10,872,716 shares of its common stock, at […]
BioSig Announces Expansion of Engineering Team
Santa Monica, CA, Feb. 26, 2019 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, today announced that the Company appointed a Senior R&D Engineer and is working on further senior […]
AliveCor Appoints Dr. Jacqueline Shreibati, Chief Medical Officer
MOUNTAIN VIEW, Calif., Feb. 26, 2019 /PRNewswire/ — AliveCor, the leader in FDA-cleared personal electrocardiogram (ECG) technology, today announced Jacqueline Shreibati, MD, MS, FACC, as Chief Medical Officer of the company. In her new role, Dr. Shreibati will lead AliveCor’s medical roadmap, developing innovative products that employ digital intelligence to improve heart care […]
Medtronic Resolute(TM) Drug-Eluting Stent (DES) Platform Receives Expanded Indication for Treatment of Chronic Total Occlusion (CTO)
DUBLIN – February 26, 2019 – Medtronic plc (NYSE:MDT) today announced the U.S. Food and Drug Administration (FDA) approval of its Resolute Drug-Eluting Stent (DES) platform (including the Resolute Onyx(TM) and Resolute Integrity(TM) DES) for the treatment of patients with coronary artery disease who have de novo chronic total occlusion (CTO), a complex […]
Boston Scientific Completes $4.3 Billion Offering of Senior Notes and Issues Redemption Notice for its 2020 Notes
MARLBOROUGH, Mass., Feb. 25, 2019 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) completed a public offering of $4.3 billion aggregate principal amount of its senior notes. The public offering consists of $850 million of 3.450% notes due 2024, $850 million of 3.750% notes due 2026, $850 million of 4.000% notes due 2029, $750 millionof 4.550% notes due 2039 and $1.0 billion of 4.700% notes due […]
TransEnterix, Inc. Reports Operating and Financial Results for the Fourth Quarter and Full Year 2018
RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–TransEnterix, Inc. (NYSE American: TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced its operating and financial results for the fourth quarter and full year 2018. Recent Highlights Sold five Senhance Systems […]
Neovasc Announces Pricing of $5 Million Public Offering of Common Shares
VANCOUVER, Feb. 26, 2019 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN / TSX: NVCN) announced today the pricing of its previously announced underwritten public offering (the “Offering”) of 11,111,111 common shares of the Company (the “Common Shares”) at a price to the public of US$0.45 per Common Share, for aggregate gross proceeds to the […]
CathWorks Adds Vice President of Global Marketing to Leadership Team
KFAR-SABA, Israel & ALISO VIEJO, Calif.–(BUSINESS WIRE)–CathWorks announced that Ramin Mousavi has joined CathWorks as Vice President of Global Marketing & Strategy. Mr. Mousavi, an experienced cardiovascular marketer, will take responsibility for the CathWorks FFRangio™ System U.S. clinical and commercial launch and direct future expansion into other global markets. Mr. Mousavi […]
LivaNova Announces Availability of Safety and Technical Information for Valve-in-Valve Procedures on Perceval Platform
LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, announced today that given the increasing viability of Valve-in-Valve (ViV) procedures, it has added new safety and technical information to the Perceval U.S. Instructions For Use (IFUs). This addition was made following completion of the Company’s application to the U.S. Food […]



